Heparinized cardiopulmonary bypass circuits and low systemic anticoagulation: an analysis of nearly 6000 patients undergoing coronary artery bypass grafting
- PMID: 20709334
- DOI: 10.1016/j.jtcvs.2010.07.003
Heparinized cardiopulmonary bypass circuits and low systemic anticoagulation: an analysis of nearly 6000 patients undergoing coronary artery bypass grafting
Abstract
Objective: Heparin coating of cardiopulmonary bypass circuits reduces the inflammatory response and increases the thromboresistance during extracorporeal circulation. These properties enables a lower systemic heparin dose, which has been shown to reduce the need for blood transfusions. Experience with this technique accumulated over 11 years has been analyzed.
Methods: All patients underwent on-pump coronary artery bypass grafting with heparin-coated circuits. Apart from some patients receiving a high intraoperative dose of aprotinin, the systemic heparin dose was reduced, with a lower level of an activated clotting time of 250 seconds during extracorporeal circulation. The overall strategy aimed at a fast-track regimen, with early extubation, minimal use of blood transfusions, and rapid postoperative recovery.
Results: Altogether, 5954 patients were included; 1131 (19.0%) were female (median age, 70 years), and 4823 were male (median age, 65 years). The median additive EuroSCORE was 3 (range, 0-14; mean 3.5 ± 2.5). No significant signs of clotting were seen in any part of the extracorporeal circuit. Bank blood products were given to 427 (7.2%) patients. Median extubation time was 1.7 hours. The stroke rate was 1.0%, transient neurologic deficits occurred in 0.7%, and perioperative myocardial infarction occurred in 1.2%. On the fifth day, 88.1% of the patients were physically rehabilitated and ready for discharge. Thirty-day mortality was 0.9% (54 patients).
Conclusions: The experience with this patient cohort including mostly low- to medium-risk patients with a relatively short cardiopulmonary bypass time indicates that coronary artery bypass grafting performed with heparin-coated circuits and reduced level of systemic heparinization is safe and results in a very satisfactory clinical course. No signs of clotting or other technical incidents were recorded.
Copyright © 2011 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
Similar articles
-
Comparison of two heparin-coated extracorporeal circuits with reduced systemic anticoagulation in routine coronary artery bypass operations.J Thorac Cardiovasc Surg. 2001 Feb;121(2):324-30. doi: 10.1067/mtc.2001.111205. J Thorac Cardiovasc Surg. 2001. PMID: 11174738 Clinical Trial.
-
Clinical and biomaterial evaluation of hyaluronan-based heparin-bonded extracorporeal circuits with reduced versus full systemic anticoagulation in reoperation for coronary revascularization.J Cardiovasc Med (Hagerstown). 2009 Feb;10(2):135-42. doi: 10.2459/JCM.0b013e32831eef9d. J Cardiovasc Med (Hagerstown). 2009. PMID: 19377380 Clinical Trial.
-
Clinical performance and biocompatibility of hyaluronan-based heparin-bonded extracorporeal circuits in different risk cohorts.Interact Cardiovasc Thorac Surg. 2010 Mar;10(3):371-6. doi: 10.1510/icvts.2009.220756. Epub 2009 Dec 21. Interact Cardiovasc Thorac Surg. 2010. PMID: 20026488 Clinical Trial.
-
Improving cardiopulmonary bypass: heparin-coated circuits.J Extra Corpor Technol. 2003 Dec;35(4):312-6. J Extra Corpor Technol. 2003. PMID: 14979422 Review.
-
Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit?Interact Cardiovasc Thorac Surg. 2012 Apr;14(4):406-14. doi: 10.1093/icvts/ivr124. Epub 2012 Jan 6. Interact Cardiovasc Thorac Surg. 2012. PMID: 22228288 Free PMC article. Review.
Cited by
-
Safety and efficacy of biocompatible perfusion strategy in a contemporary series of patients undergoing coronary artery bypass grafting - a two-center study.J Cardiothorac Surg. 2014 Dec 18;9:196. doi: 10.1186/s13019-014-0196-3. J Cardiothorac Surg. 2014. PMID: 25519179 Free PMC article.
-
VV extracorporeal life support for the Third Millennium: will we need anticoagulation?J Thorac Dis. 2018 Mar;10(Suppl 5):S698-S706. doi: 10.21037/jtd.2017.11.89. J Thorac Dis. 2018. PMID: 29732189 Free PMC article. Review.
-
2024 EACTS/EACTAIC/EBCP Guidelines on cardiopulmonary bypass in adult cardiac surgery.Interdiscip Cardiovasc Thorac Surg. 2025 Feb 5;40(2):ivaf002. doi: 10.1093/icvts/ivaf002. Interdiscip Cardiovasc Thorac Surg. 2025. PMID: 39949317 Free PMC article. No abstract available.
-
A randomized study of coronary artery bypass surgery performed with the Resting Heart™ System utilizing a low vs a standard dosage of heparin.Interact Cardiovasc Thorac Surg. 2012 Nov;15(5):834-9. doi: 10.1093/icvts/ivs345. Epub 2012 Aug 21. Interact Cardiovasc Thorac Surg. 2012. PMID: 22914806 Free PMC article. Clinical Trial.
-
A Novel C1-Esterase Inhibitor Oxygenator Coating Prevents FXII Activation in Human Blood.Biomolecules. 2020 Jul 13;10(7):1042. doi: 10.3390/biom10071042. Biomolecules. 2020. PMID: 32668719 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical